|
Gene: RGS2 |
Gene summary for RGS2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RGS2 | Gene ID | 5997 |
Gene name | regulator of G protein signaling 2 | |
Gene Alias | G0S8 | |
Cytomap | 1q31.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R939 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5997 | RGS2 | CA_HPV_1 | Human | Cervix | CC | 1.47e-09 | 5.63e-01 | 0.0264 |
5997 | RGS2 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 5.45e-07 | -4.49e-01 | 0.0208 |
5997 | RGS2 | CCI_1 | Human | Cervix | CC | 9.73e-04 | -7.04e-01 | 0.528 |
5997 | RGS2 | CCI_2 | Human | Cervix | CC | 1.72e-04 | -7.43e-01 | 0.5249 |
5997 | RGS2 | CCI_3 | Human | Cervix | CC | 2.81e-07 | -7.33e-01 | 0.516 |
5997 | RGS2 | CCII_1 | Human | Cervix | CC | 4.27e-14 | -7.65e-01 | 0.3249 |
5997 | RGS2 | Tumor | Human | Cervix | CC | 4.47e-16 | -5.82e-01 | 0.1241 |
5997 | RGS2 | sample3 | Human | Cervix | CC | 1.87e-16 | -5.59e-01 | 0.1387 |
5997 | RGS2 | H2 | Human | Cervix | HSIL_HPV | 5.20e-22 | -6.61e-01 | 0.0632 |
5997 | RGS2 | L1 | Human | Cervix | CC | 1.59e-06 | -6.07e-01 | 0.0802 |
5997 | RGS2 | T3 | Human | Cervix | CC | 1.06e-16 | -6.00e-01 | 0.1389 |
5997 | RGS2 | LZE7T | Human | Esophagus | ESCC | 3.52e-07 | 3.32e-02 | 0.0667 |
5997 | RGS2 | LZE8T | Human | Esophagus | ESCC | 1.54e-02 | -2.46e-01 | 0.067 |
5997 | RGS2 | LZE21D1 | Human | Esophagus | HGIN | 6.03e-05 | -1.85e-01 | 0.0632 |
5997 | RGS2 | LZE24T | Human | Esophagus | ESCC | 2.05e-03 | -8.31e-02 | 0.0596 |
5997 | RGS2 | LZE21T | Human | Esophagus | ESCC | 3.37e-02 | -1.36e-01 | 0.0655 |
5997 | RGS2 | P2T-E | Human | Esophagus | ESCC | 1.33e-11 | -2.61e-01 | 0.1177 |
5997 | RGS2 | P4T-E | Human | Esophagus | ESCC | 5.10e-14 | 8.06e-01 | 0.1323 |
5997 | RGS2 | P5T-E | Human | Esophagus | ESCC | 1.59e-36 | 1.15e+00 | 0.1327 |
5997 | RGS2 | P8T-E | Human | Esophagus | ESCC | 4.92e-08 | -1.02e-01 | 0.0889 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000193333 | Thyroid | ATC | negative regulation of protein phosphorylation | 186/6293 | 342/18723 | 1.43e-15 | 1.08e-13 | 186 |
GO:004232634 | Thyroid | ATC | negative regulation of phosphorylation | 203/6293 | 385/18723 | 5.30e-15 | 3.53e-13 | 203 |
GO:000641735 | Thyroid | ATC | regulation of translation | 236/6293 | 468/18723 | 2.39e-14 | 1.34e-12 | 236 |
GO:001604927 | Thyroid | ATC | cell growth | 241/6293 | 482/18723 | 4.27e-14 | 2.35e-12 | 241 |
GO:003134623 | Thyroid | ATC | positive regulation of cell projection organization | 186/6293 | 353/18723 | 7.99e-14 | 4.23e-12 | 186 |
GO:005134834 | Thyroid | ATC | negative regulation of transferase activity | 144/6293 | 268/18723 | 7.63e-12 | 2.91e-10 | 144 |
GO:000155826 | Thyroid | ATC | regulation of cell growth | 201/6293 | 414/18723 | 1.57e-10 | 4.76e-09 | 201 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
GO:007190025 | Thyroid | ATC | regulation of protein serine/threonine kinase activity | 176/6293 | 359/18723 | 8.35e-10 | 2.17e-08 | 176 |
GO:000646925 | Thyroid | ATC | negative regulation of protein kinase activity | 114/6293 | 212/18723 | 1.06e-09 | 2.69e-08 | 114 |
GO:003367325 | Thyroid | ATC | negative regulation of kinase activity | 122/6293 | 237/18723 | 9.19e-09 | 1.94e-07 | 122 |
GO:004858823 | Thyroid | ATC | developmental cell growth | 114/6293 | 234/18723 | 1.11e-06 | 1.44e-05 | 114 |
GO:006053724 | Thyroid | ATC | muscle tissue development | 181/6293 | 403/18723 | 1.27e-06 | 1.62e-05 | 181 |
GO:001097614 | Thyroid | ATC | positive regulation of neuron projection development | 82/6293 | 163/18723 | 7.43e-06 | 7.61e-05 | 82 |
GO:001470622 | Thyroid | ATC | striated muscle tissue development | 168/6293 | 384/18723 | 1.91e-05 | 1.73e-04 | 168 |
GO:004592622 | Thyroid | ATC | negative regulation of growth | 115/6293 | 249/18723 | 2.34e-05 | 2.06e-04 | 115 |
GO:003030813 | Thyroid | ATC | negative regulation of cell growth | 90/6293 | 188/18723 | 3.35e-05 | 2.78e-04 | 90 |
GO:004269216 | Thyroid | ATC | muscle cell differentiation | 165/6293 | 384/18723 | 7.17e-05 | 5.46e-04 | 165 |
GO:004544423 | Thyroid | ATC | fat cell differentiation | 105/6293 | 229/18723 | 7.42e-05 | 5.62e-04 | 105 |
GO:003424923 | Thyroid | ATC | negative regulation of cellular amide metabolic process | 121/6293 | 273/18723 | 1.36e-04 | 9.57e-04 | 121 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049218 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
hsa0492111 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
hsa049219 | Oral cavity | EOLP | Oxytocin signaling pathway | 36/1218 | 154/8465 | 1.79e-03 | 6.08e-03 | 3.58e-03 | 36 |
hsa040224 | Oral cavity | EOLP | cGMP-PKG signaling pathway | 36/1218 | 167/8465 | 7.34e-03 | 2.12e-02 | 1.25e-02 | 36 |
hsa0492112 | Oral cavity | EOLP | Oxytocin signaling pathway | 36/1218 | 154/8465 | 1.79e-03 | 6.08e-03 | 3.58e-03 | 36 |
hsa0402211 | Oral cavity | EOLP | cGMP-PKG signaling pathway | 36/1218 | 167/8465 | 7.34e-03 | 2.12e-02 | 1.25e-02 | 36 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RGS2 | SNV | Missense_Mutation | rs759895235 | c.518C>T | p.Ala173Val | p.A173V | P41220 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RGS2 | SNV | Missense_Mutation | c.93A>C | p.Glu31Asp | p.E31D | P41220 | protein_coding | tolerated(0.45) | benign(0.099) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
RGS2 | SNV | Missense_Mutation | c.349G>A | p.Glu117Lys | p.E117K | P41220 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
RGS2 | SNV | Missense_Mutation | c.300N>G | p.Phe100Leu | p.F100L | P41220 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
RGS2 | SNV | Missense_Mutation | c.595T>A | p.Cys199Ser | p.C199S | P41220 | protein_coding | deleterious(0) | possibly_damaging(0.447) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
RGS2 | SNV | Missense_Mutation | rs149228054 | c.315C>A | p.Phe105Leu | p.F105L | P41220 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RGS2 | SNV | Missense_Mutation | novel | c.247G>T | p.Ala83Ser | p.A83S | P41220 | protein_coding | tolerated(1) | benign(0.013) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RGS2 | insertion | Frame_Shift_Ins | rs775439827 | c.183_184insA | p.Ser64LysfsTer12 | p.S64Kfs*12 | P41220 | protein_coding | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | ||
RGS2 | SNV | Missense_Mutation | novel | c.445N>G | p.Asn149Asp | p.N149D | P41220 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RGS2 | SNV | Missense_Mutation | rs149228054 | c.315N>A | p.Phe105Leu | p.F105L | P41220 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5997 | RGS2 | NA | haloperidol | HALOPERIDOL | 27023437 | |
5997 | RGS2 | NA | antipsychotics | 18347610 |
Page: 1 |